Abstract
Murine gammaherpesvirus 68 (MHV68) is a naturally occurring pathogen of murid rodents that is genetically related to the human gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV). Viral, immunologic, and disease parameters following experimental infection of laboratory mice with MHV68 closely resemble what occurs during primary EBV infection of humans, which suggests that MHV68 infection of mice offers a small animal model to study in general the pathogenesis of gammaherpesvirus infections. Diseases elicited by MHV68 infection include lymphoproliferative diseases, idiopathic pulmonary fibrosis, and autoimmune diseases, ailments also associated with EBV infection of humans. Furthermore, MHV68 infection also is linked to the development of vasculitis, encephalomyelitis, and other disorders that resemble pathologies with viral and nonviral etiologies in humans. This review aims to provide an overview of MHV68-associated diseases in infected mice that may provide a model for understanding basic mechanisms by which similar diseases in humans occur and can be treated.
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
14.1 Introduction
Murine gammaherpesvirus 68 (MHV68) is a naturally occurring virus that was originally isolated from Slovakian bank voles and is endemic in European wood mice [1,2,3]. MHV68 is genetically related to the human gammaherpesviruses (GHVs), Epstein-Barr virus (EBV), and Kaposi sarcoma-associated herpesvirus (KSHV), possessing a genome that is collinear with those of EBV and KSHV and contains large blocks of conserved genes with interspersed unique genes as well [1, 4, 5]. Following intranasal infection of mice, MHV68 undergoes acute infection in the lungs and nasal epithelium and establishes latency, a nonproductive, quiescent infection characterized by minimal viral gene expression and maintenance of the viral genome, in cells of the spleen and blood [6,7,8,9]. Productive replication mainly involves epithelial and mononuclear cells in the lungs, with acute infection resolving by approximately 2 weeks post-infection [10]. Acute replication precedes and is thought to be necessary for lifelong latent infection in lymphoid tissues, where B cells serve as the major latent reservoir for MHV68 in the spleen [6]. Peritoneal macrophages and lung epithelial cells also harbor latent MHV68 genomes [10, 11].
MHV68 infection of mice results in a variety of pathologies that resemble EBV-associated diseases and other human disorders. Mice chronically infected with MHV68 develop a marked splenomegaly and lymphoproliferative diseases (LPDs), similar to what is observed in patients infected with EBV [12,13,14]. MHV68 infection induces multi-organ fibrosis and vasculitis in interferon gamma receptor knockout (IFNγR-/-) mice [15,16,17]. In other disease models, MHV68 infection promotes systemic inflammation, exacerbates autoimmune encephalomyelitis, and influences development of other pathologies [18, 19]. Here, we will discuss MHV68-related diseases and the potential value of this small animal model for the study of similar diseases associated with infections by human GHVs.
14.2 MHV68-Associated Diseases
14.2.1 MHV68-Associated Lymphoproliferative Diseases
Infection of laboratory mice with MHV68 leads to a variety of pathological changes that mirror EBV-associated LPDs and other malignancies. Following intranasal infection of wild-type mice with MHV68, acute infection in the lung develops and is subsequently cleared, followed by the establishment of latency in the spleen [20, 21]. Latency establishment is accompanied by splenomegaly, which is characterized by a two- to threefold increase in the number of spleen cells, with the largest increase occurring in the CD8+ T cell population [13]. Polyclonal B-cell activation and autoantibody production also occur [13]. This is similar to what occurs during EBV-induced infectious mononucleosis in humans [22, 23]. Development of splenomegaly in MHV68 infection requires CD4+ T cells and organized secondary lymphoid tissue [13, 24, 25]. CD25-mediated IL-2 signaling also is necessary for the CD8+ T cell mononucleosis that occurs [26].
BALB/c mice chronically infected with MHV68 develop LPDs, including high-grade lymphomas that resemble centroblastic or plasmablastic non-Hodgkin lymphomas seen in humans [12]. MHV68-associated lymphomas primarily occur in older mice (0.75–3 years of age), and lymphoma incidence is greatly increased when infected mice are treated with the immunosuppressive drug cyclosporin A [12]. Since cyclosporin A functions chiefly through inhibition of T cell function, this finding strongly suggests that T cells are important for limiting tumor growth in MHV68-infected mice. Indeed, adoptive transfer of CD4+ T cells from infected mice promotes regression of lymphomas that developed following subcutaneous injection of an MHV68-positive B-cell lymphoma line, S11, isolated from a tumor-bearing BALB/c mouse [27]. Although MHV68 does not appear to transform primary murine B cells in culture, murine fetal liver-derived B cells are transformed by MHV68 into plasmablast-like B cells in vitro [28]. Similar to S11 cells, when these plasmablast-like B cells are injected into immunodeficient mice, the transformed B cells induce lymphomas that can be controlled by both CD4+ and CD8+ T cells [29]. Together, these findings illustrate (i) that MHV68 infection can cause lymphomas and (ii) that T cells are important for controlling infection-associated lymphomas.
MHV68 infection of BALB/c2 microglobulin (B2M)-deficient mice (BALB B2M-/-) also results in B-cell lymphoma and an atypical lymphoid hyperplasia (ALH) [14]. ALH pathologically is differentially regulated by MHV68 genes and resembles posttransplant lymphoproliferative disease observed in some EBV-infected individuals that are immune suppressed for solid organ transplants [30, 31]. B2M is a critical component of the major histocompatibility I (MHCI) complex, a cell surface receptor necessary for CD8+ T cells to engage target cells [32]. This further illustrates the importance of T cells in preventing MHV68-associated LPDs.
Lymphomatoid granulomatosis (LYG) is a rare systemic angiodestructive LPD caused by the combination of EBV infection and immunosuppression [33, 34]. LYG mostly affects the lungs and is recently characterized as B-cell lymphomas with prominent pulmonary involvement [33]. MHV68-infected IFNγR-/- mice also develop pulmonary B-cell lymphomas which closely mimic EBV-associated LYG in human [35].
Nevertheless, there are differences between EBV-associated LPDs in humans and MHV68-associated LPDs in mice. For example, CD8+ T cell lymphocytosis associated with EBV-induced mononucleosis is predominantly an outgrowth of T cells responding to viral lytic epitopes [36, 37]. In contrast MHV68-induced mononucleosis in C57BL/6 mice represents expansion of CD8+ T cells that encode a Vβ4 T cell receptor that is not reactive to viral epitopes and appears to be stimulated by latently infected B cells [38, 39]. However, the striking pathological similarities between EBV-associated LPDs and the corresponding syndrome in MHV68-infected mice highlight MHV68 as a valuable small animal model for studying fundamental issues in gammaherpesvirus-associated LPD pathogenesis in a natural host.
14.2.2 MHV68-Associated Fibrosis
Several reports associate EBV infection with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fibrotic lung disorder of unknown etiology that is a risk factor for lung cancer development [40,41,42,43]. Although EBV is frequently detected in lung tissues of patients with IPF, an etiologic role for EBV in IPF is not established REF. Interestingly, MHV68 infection of IFNγR-/- mice leads to multi-organ fibrosis, which occurs in the lung, spleen, mediastinal lymph nodes, and liver of these mice [15, 16, 44, 45]. Lung fibrosis in MHV68-infected IFNγR-/- mice shares similar pathology to IPF in humans [45]. Mechanistic studies show that both viral and cellular factors are involved in MHV68-induced fibrosis in IFNγR-/- mice. Persistent MHV68 lytic replication apparently is essential for induction or exacerbation of IPF, because severe fibrosis is ameliorated in MHV68-infected IFNγR-/- mice that receive antiviral treatment and in IFNγR-/- mice infected with a reactivation-defective MHV68 mutant that fails to express v-cyclin [46]. Moreover, MHV68 superantigen-like M1 protein and activated Vβ4+ CD8+ T cells, which are driven to expand by M1, also are required for MHV68-induced inflammation and fibrosis in IFN-γR-/- mice [47, 48]. Additionally, inhibition of NF-κB signaling reduces virus persistence and pulmonary fibrosis in MHV68-infected IFNγR-/- mice, indicating that NF-κB signaling also is important for MHV68-induced pulmonary fibrosis [49]. Thus, MHV68 infection of IFNγR-/- mice could be used to model the association of gammaherpesvirus infection with IPF and define underlying molecular mechanisms of disease.
MHV68 infection of bleomycin-resistant BALB/c mice has also been used to study the association between GHV infection and IPF. Bleomycin-induced fibrosis is widely used experimental model for lung fibrosis occurring during chemotherapy [50]. BALB/c mice are inherently resistant to lung fibrosis due to bleomycin treatment and do not develop pulmonary fibrosis when infected with MHV68. However, when BALB/c mice are simultaneously infected with MHV68 and treated with bleomycin, lung fibrosis occurs [51], indicating that MHV68 functions as a cofactor in bleomycin-induced fibrosis. Another study demonstrated that TLR9 signaling protects against MHV68-induced exacerbation of lung fibrosis induced by bleomycin in BALB/c mice [52]. These findings support the role of GHV infection in human IPD, and future development of the MHV68/bleomycin model should further explore mechanisms by which GHV infection functions as a cofactor in the pathogenesis of pulmonary fibrosis.
Finally, MHV68 infection of IFNγ deficient (IFNγ-/-) mice on the BALB/c genetic background results in acute lethal pneumonia that is dependent on MHV68-encoded v-cyclin and v-bcl-2 [53]. However, whether MHV68-induced pneumonia in IFNγ-/- mice is pathologically similar to EBV-associated pneumonia, which mainly occurs in children and transplant patients, is not yet clear [54,55,56,57].
In addition to lung fibrosis, MHV68 infection of IFNγR-/- mice also induces fibrosis in the spleen. The prominent feature of splenic pathology in infected IFNγR-/- mice is a loss of B cells and CD4+ and CD8+ T cells, which correlates with significant changes in cytokines and chemokines in spleens. In contrast, a dramatic increase in T and B lymphocytes in peripheral blood occurs [15, 44]. CD8+ T cells are the major mediators of splenic damage, since depletion of CD8+ T cells completely reverses the pathological and histological changes in spleens of these mice. However, although removal of CD4+ T cells reverses the weight loss and reduces the number of infective centers, some pathological changes are still observed in CD4+ T cell-depleted mice. This suggests that CD4+ T cells are not the dominant mediators but still play an important role in splenic fibrosis [44].
Furthermore, MHV68 infection of IFNγR-/- mice leads to enhanced production of Th2 cytokines IL-5, IL-13, and IL-21 and increased expression of CCR4 in the spleens of infected mice [16]. This drives alternative activation of macrophages to produce arginase 1 (ARG1) and found in inflammatory zone 1 (FIZZ1)/resistin-like molecule-α (RELMα) to promote fibrotic disease in the spleen [16, 58]. Though EBV infection is not directly linked to fibrotic disease of the spleen in humans, the data from MHV68 infections suggest a role for GHV infection in such diseases. This model may therefore hold future relevance for understanding how viruses influence splenic fibrosis in general.
14.2.3 MHV68 Impact on Autoimmune Diseases
Multiple sclerosis (MS) is an autoimmune disorder in which the immune system attacks the central nervous system (CNS), damaging the myelin sheath of nerve cells in the brain and spinal cord. EBV is etiologically linked to MS [59,60,61]; however mechanisms by which EBV influences MS pathogenesis are not known. In mice induction of inflammatory immune responses in the brain triggers an MS-like syndrome known as experimental autoimmune encephalomyelitis (EAE) [62, 63]. Because MHV68 replicates in the mouse brain, infecting microglia and astrocytes [64, 65], and globally influences immune activation in infected animals [66], the impact of MHV68 infection on EAE pathogenesis was evaluated. Latent MHV68 infection enhances EAE pathogenesis and central nervous system pathology in a manner reminiscent of human MS [19, 67]. This observation demonstrates that GHV infection can influence the course of disease in CNS autoimmune disorders and highlights the potential of these small animal models in facilitating an understanding of mechanisms by which EBV influences MS.
EBV infection also is linked to development of lupus in humans, an autoimmune disease in which healthy tissues are attacked by the individual’s immune system, leading to swelling and damage of various tissues of the body. In contrast to EAE models, MHV68 infection protects, rather than exacerbates, lupus-prone mice from the development and progression of autoimmunity [68]. Together, these findings demonstrate that GHV infection influences the course of CNS autoimmune disease. However, the data also demonstrate that pathogenesis is likely a multifactorial process in which GHV infections may have pleiotropic impacts on disease progression.
The impact of MHV68 infection in other mouse models of autoimmune disease also has been evaluated. For instance, IL10−/− mice are prone to developing inflammatory bowel disease (IBD), and infection with MHV68 promotes more rapid and severe disease in these mice [69]. This finding is similar to the observation that EBV infection correlates with disease severity in some IBD patients [70,71,72,73,74]. In contrast, MHV68 infection of nonobese diabetic (NOD) mice, a mouse model for evaluating type I diabetes (T1D), significantly delays diabetes onset [75], which supports the hypothesis that viruses are potential regulators of T1D [76,77,78]. Furthermore, transgenic mice expressing MHV68 chemokine decoy receptor M3 in beta cells are remarkably resistant to diabetes induced by multiple low doses of streptozotocin [79]. This suggests the importance of specific viral factors in regulating T1D. Together, these data highlight the manner in which MHV68 studies could be employed to define roles for GHVs in intestinal diseases and diabetes.
14.2.4 MHV68-Related Vascular and Ductal Disorders
In addition to lymphoma development and fibrosis, MHV68 causes severe large-vessel arteritis associated with lipid accumulation in the vessel wall and luminal thrombosis in IFNγR-/- mice. Lesions that develop are similar to those seen during the acute inflammatory phase of Takayasu arteritis, the nongranulomatous variant of temporal arteritis and Kawasaki diseases [17], suggesting possible GHV etiologies in these pathologies and demonstrating the utility of MHV68 infection of mice in dissecting GHV roles in human vasculitis. Furthermore, MHV68 induces chronic inflammation of intrahepatic bile ducts in infected IFNγR-/- mice, which is pathologically similar to the human fibrotic liver disorder primary sclerosing cholangitis [80]. Additionally, MHV68 reactivation from latency induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice. These lesions are associated with elevated neutrophil elastase, which is produced by pulmonary artery smooth muscle cells and linked to experimental and clinical pulmonary vascular disease [81, 82]. Finally, MHV68 infection in mice also induces phenotypes that mimic rare diseases such as systemic lymphocytosis following gastric instillation and fatigue [83, 84]. MHV68 may therefore provide a useful model for the study of fatigue and other physiologic and behavioral perturbations that occur during acute and chronic infection with gammaherpesviruses.
14.3 Remarks and Perspectives
Human gammaherpesviruses are exquisitely species restricted, which limits possible approaches for defining precise mechanisms by which these viruses cause disease. The beauty of small animal models of viral pathogenesis is that they enable evaluations of both viral and host determinants of disease in experimentally controlled settings. In contrast, analogous studies of GHV infections in humans would require the presence of naturally occurring mutations in either virus or host, paired with the ability to identify individuals and viruses that possess such genetic variants. Even then, the studies would be necessarily associative, observational, and potentially influenced by numerous outside variables due to environment, lifestyle, additional genetic variations, age, coinfections, etc. The use of humanized mice, immunodeficient animals in which the immune system is reconstituted by human stem cells, allows an experimental system for evaluating certain aspects of GHV infection in human cells. But again the system is still genetically limited and may not faithfully recapitulate natural cellular development and cell-cell interactions, and not all tissues in the reconstituted mouse are of human origin. Humanized mice are also very expensive. Hence, the capacity to study a genetically related pathogen (MHV68) in a natural host (rodents) offers a powerful tool for understanding virus-host interactions in GHV infection-associated diseases. Here, infections of inbred mice with MHV68 provide a simplified and standardized analysis of immune responses against the virus and eliminate many potential experimental variables. Moreover, the ease of genetically manipulating both virus and host further highlights the tractability of the MHV68 system. Indeed, genetically modified mice and viruses enable many of disease models described above.
However, this is not to say that infection of mice with MHV68 is identical to human infections with EBV or KSHV. Clearly mice are not humans, and it is naïve to think that all aspects of the host response will be identical in two quite divergent species. Further, while genetic diversity is an experimental problem, genetic polymorphisms from human to human and population to population undoubtedly influence the pathogenesis and outcome of infection by GHVs.
Along these same lines, MHV68 is not EBV or KSHV. While all GHVs (and herpesviruses in general) possess blocks of conserved genes, each virus also encodes unique proteins that are not shared with their GHV relatives. These genes maintain no vestige of sequence homology and may have developed through convergent evolution to satisfy unique requirements of the virus-host relationship. It is however interesting to note that the products of these divergent genes likely perform conserved functions, for instance, both LMP2a of EBV and M2 of MHV68 manipulate B-cell survival and differentiation [85]. If these unique genes are under selection from the host, it is equally possible that they have simply diverged over millennia at a rate that made them nonhomologous at the sequence level by modern informatics techniques while maintaining critical functions. Perhaps the key take-home points are these: MHV68 provides a highly tractable experimental system for understanding how GHVs influence disease in a variety of experimental models. Though obvious differences exist between human and mouse infections, the data produced in the mouse models are real and may offer invaluable insights into factors that influence similar diseases in humans. As such, MHV68 infection of mice can serve as powerful tool in the arsenal for illuminating previously unappreciated factors and cofactors that influence human disease and allow for preclinical testing of novel hypotheses for treating related diseases.
References
Blaskovic D, Stancekova M, Svobodova J, Mistrikova J (1980) Isolation of five strains of herpesviruses from two species of free living small rodents. Acta Virol 24:468
Mistrikova J, Blaskovic D (1985) Ecology of the murine alphaherpesvirus and its isolation from lungs of rodents in cell culture. Acta Virol 29:312–317
Svobodova J, Blaskovic D, Mistrikova J (1982) Growth characteristics of herpesviruses isolated from free living small rodents. Acta Virol 26:256–263
Efstathiou S, Ho YM, Hall S, Styles CJ, Scott SD, Gompels UA (1990) Murine herpesvirus 68 is genetically related to the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri. J Gen Virol 71(Pt 6):1365–1372
Virgin HW, Latreille P, Wamsley P, Hallsworth K, Weck KE, Dal Canto AJ, Speck SH (1997) Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 71:5894–5904
Sunil-Chandra NP, Efstathiou S, Nash AA (1992) Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J Gen Virol 73(Pt 12):3275–3279
Weck KE, Barkon ML, Yoo LI, Speck SH, Virgin HI (1996) Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. J Virol 70:6775–6780
Weck KE, Kim SS, Virgin HI, Speck SH (1999) B cells regulate murine gammaherpesvirus 68 latency. J Virol 73:4651–4661
Milho R, Smith CM, Marques S, Alenquer M, May JS, Gillet L, Gaspar M, Efstathiou S, Simas JP, Stevenson PG (2009) In vivo imaging of murid herpesvirus-4 infection. J Gen Virol 90:21–32
Stewart JP, Usherwood EJ, Ross A, Dyson H, Nash T (1998) Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med 187:1941–1951
Weck KE, Kim SS, Virgin HI, Speck SH (1999) Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J Virol 73:3273–3283
Sunil-Chandra NP, Arno J, Fazakerley J, Nash AA (1994) Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68. Am J Pathol 145:818–826
Usherwood EJ, Ross AJ, Allen DJ, Nash AA (1996) Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. J Gen Virol 77(Pt 4):627–630
Tarakanova VL, Suarez F, Tibbetts SA, Jacoby MA, Weck KE, Hess JL, Speck SH, Virgin HW (2005) Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. J Virol 79:14668–14679
Ebrahimi B, Dutia BM, Brownstein DG, Nash AA (2001) Murine gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in interferon-gamma receptor knockout mice. Am J Pathol 158:2117–2125
Gangadharan B, Hoeve MA, Allen JE, Ebrahimi B, Rhind SM, Dutia BM, Nash AA (2008) Murine gammaherpesvirus-induced fibrosis is associated with the development of alternatively activated macrophages. J Leukoc Biol 84:50–58
Weck KE, Dal Canto AJ, Gould JD, O’Guin AK, Roth KA, Saffitz JE, Speck SH, Virgin HW (1997) Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 3:1346–1353
Park S, Buck MD, Desai C, Zhang X, Loginicheva E, Martinez J, Freeman ML, Saitoh T, Akira S, Guan JL, He YW, Blackman MA, Handley SA, Levine B, Green DR, Reese TA, Artyomov MN, Virgin HW (2016) Autophagy genes enhance murine Gammaherpesvirus 68 reactivation from latency by preventing virus-induced systemic inflammation. Cell Host Microbe 19:91–101
Peacock JW, Elsawa SF, Petty CC, Hickey WF, Bost KL (2003) Exacerbation of experimental autoimmune encephalomyelitis in rodents infected with murine gammaherpesvirus-68. Eur J Immunol 33:1849–1858
Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA (1992) Virological and pathological features of mice infected with murine gamma-herpesvirus 68. J Gen Virol 73(Pt 9):2347–2356
Cardin RD, Brooks JW, Sarawar SR, Doherty PC (1996) Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 184:863–871
Cantani A, Mastrantoni F (1989) Recent advances on Epstein-Barr virus infectious mononucleosis. Riv Eur Sci Med Farmacol 11:41–44
Flano E, Woodland DL, Blackman MA (2002) A mouse model for infectious mononucleosis. Immunol Res 25:201–217
Lee BJ, Santee S, Von Gesjen S, Ware CF, Sarawar SR (2000) Lymphotoxin-alpha-deficient mice can clear a productive infection with murine gammaherpesvirus 68 but fail to develop splenomegaly or lymphocytosis. J Virol 74:2786–2792
Ehtisham S, Sunil-Chandra NP, Nash AA (1993) Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. J Virol 67:5247–5252
Molloy M, Zhang W, Usherwood E (2010) Mononucleosis and antigen-driven T cell responses have different requirements for interleukin-2 signaling in murine gammaherpesvirus infection. J Virol 84:10923–10927
Robertson KA, Usherwood EJ, Nash AA (2001) Regression of a murine gammaherpesvirus 68-positive b-cell lymphoma mediated by CD4 T lymphocytes. J Virol 75:3480–3482
Liang X, Paden CR, Morales FM, Powers RP, Jacob J, Speck SH (2011) Murine gamma-herpesvirus immortalization of fetal liver-derived B cells requires both the viral cyclin D homolog and latency-associated nuclear antigen. PLoS Pathog 7:e1002220
Liang X, Crepeau RL, Zhang W, Speck SH, Usherwood EJ (2013) CD4 and CD8 T cells directly recognize murine gammaherpesvirus 68-immortalized cells and prevent tumor outgrowth. J Virol 87:6051–6054
Good DJ, Gascoyne RD (2009) Atypical lymphoid hyperplasia mimicking lymphoma. Hematol Oncol Clin North Am 23:729–745
Tarakanova VL, Kreisel F, White DW, Virgin HW (2008) Murine gammaherpesvirus 68 genes both induce and suppress lymphoproliferative disease. J Virol 82:1034–1039
Peterson PA, Rask L, Ostberg L (1977) Beta2-microglobulin and the major histocompatibility complex. Adv Cancer Res 24:115–163
Dunleavy K, Roschewski M, Wilson WH (2012) Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. Curr Hematol Malig Rep 7:208–215
Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES (1996) Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 87:4531–4537
Lee KS, Groshong SD, Cool CD, Kleinschmidt-DeMasters BK, van Dyk LF (2009) Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease. Cancer Res 69:5481–5489
Callan MF, Steven N, Krausa P, Wilson JD, Moss PA, Gillespie GM, Bell JI, Rickinson AB, McMichael AJ (1996) Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 2:906–911
Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O’Callaghan CA, Steven N, McMichael AJ, Rickinson AB (1998) Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187:1395–1402
Tripp RA, Hamilton-Easton AM, Cardin RD, Nguyen P, Behm FG, Woodland DL, Doherty PC, Blackman MA (1997) Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? J Exp Med 185:1641–1650
Doherty PC, Tripp RA, Hamilton-Easton AM, Cardin RD, Woodland DL, Blackman MA (1997) Tuning into immunological dissonance: an experimental model for infectious mononucleosis. Curr Opin Immunol 9:477–483
Vergnon JM, Vincent M, de The G, Mornex JF, Weynants P, Brune J (1984) Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet 2:768–771
Egan JJ, Woodcock AA, Stewart JP (1997) Viruses and idiopathic pulmonary fibrosis. Eur Respir J 10:1433–1437
Stewart JP, Egan JJ, Ross AJ, Kelly BG, Lok SS, Hasleton PS, Woodcock AA (1999) The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 159:1336–1341
Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K (2000) Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 55:958–961
Dutia BM, Clarke CJ, Allen DJ, Nash AA (1997) Pathological changes in the spleens of gamma interferon receptor-deficient mice infected with murine gammaherpesvirus: a role for CD8 T cells. J Virol 71:4278–4283
Vannella KM, Moore BB (2008) Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 1:2
Mora AL, Torres-Gonzalez E, Rojas M, Xu J, Ritzenthaler J, Speck SH, Roman J, Brigham K, Stecenko A (2007) Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med 175:1139–1150
Evans AG, Moser JM, Krug LT, Pozharskaya V, Mora AL, Speck SH (2008) A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates chronic infection and immunopathology. J Exp Med 205:669–684
O’Flaherty BM, Matar CG, Wakeman BS, Garcia A, Wilke CA, Courtney CL, Moore BB, Speck SH (2015) CD8+ T cell response to Gammaherpesvirus infection mediates inflammation and fibrosis in interferon gamma receptor-deficient mice. PLoS One 10:e0135719
Krug LT, Torres-Gonzalez E, Qin Q, Sorescu D, Rojas M, Stecenko A, Speck SH, Mora AL (2010) Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis. Am J Pathol 177:608–621
Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R (2002) Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 83:111–119
Lok SS, Haider Y, Howell D, Stewart JP, Hasleton PS, Egan JJ (2002) Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J 20:1228–1232
Luckhardt TR, Coomes SM, Trujillo G, Stoolman JS, Vannella KM, Bhan U, Wilke CA, Moore TA, Toews GB, Hogaboam C, Moore BB (2011) TLR9-induced interferon beta is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 4:18
Lee KS, Cool CD, van Dyk LF (2009) Murine gammaherpesvirus 68 infection of gamma interferon-deficient mice on a BALB/c background results in acute lethal pneumonia that is dependent on specific viral genes. J Virol 83:11397–11401
Andiman WA, McCarthy P, Markowitz RI, Cormier D, Horstmann DM (1981) Clinical, virologic, and serologic evidence of Epstein-Barr virus infection in association with childhood pneumonia. J Pediatr 99:880–886
Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ (2010) Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis 12:284–291
Krumbholz A, Sandhaus T, Gohlert A, Heim A, Zell R, Egerer R, Breuer M, Straube E, Wutzler P, Sauerbrei A (2010) Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol 199:317–322
Abughali N, Khiyami A, Birnkrant DJ, Kumar ML (2002) Severe respiratory syncytial virus pneumonia associated with primary Epstein-Barr virus infection. Pediatr Pulmonol 33:395–398
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23–35
Ascherio A, Munch M (2000) Epstein-Barr virus and multiple sclerosis. Epidemiology 11:220–224
Ascherio A, Munger KL, Lunemann JD (2012) The initiation and prevention of multiple sclerosis. Nat Rev Neurol 8:602–612
Tselis A (2012) Epstein-Barr virus cause of multiple sclerosis. Curr Opin Rheumatol 24:424–428
Mackay IR, Carnegie PR, Coates AS (1973) Immunopathological comparisons between experimental autoimmune encephalomyelitis and multiple sclerosis. Clin Exp Immunol 15:471–482
Swanborg RH (1995) Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 77:4–13
Terry LA, Stewart JP, Nash AA, Fazakerley JK (2000) Murine gammaherpesvirus-68 infection of and persistence in the central nervous system. J Gen Virol 81:2635–2643
Taylor WR, Rasley A, Bost KL, Marriott I (2003) Murine gammaherpesvirus-68 infects microglia and induces high levels of pro-inflammatory cytokine production. J Neuroimmunol 136:75–83
Stevenson PG, Doherty PC (1998) Kinetic analysis of the specific host response to a murine gammaherpesvirus. J Virol 72:943–949
Casiraghi C, Shanina I, Cho S, Freeman ML, Blackman MA, Horwitz MS (2012) Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis. PLoS Pathog 8:e1002715
Larson JD, Thurman JM, Rubtsov AV, Claypool D, Marrack P, van Dyk LF, Torres RM, Pelanda R (2012) Murine gammaherpesvirus 68 infection protects lupus-prone mice from the development of autoimmunity. Proc Natl Acad Sci U S A 109:E1092–E1100
Nelson DA, Petty CC, Bost KL (2009) Infection with murine gammaherpesvirus 68 exacerbates inflammatory bowel disease in IL-10-deficient mice. Inflamm Res 58:881–889
Bertalot G, Villanacci V, Gramegna M, Orvieto E, Negrini R, Saleri A, Terraroli C, Ravelli P, Cestari R, Viale G (2001) Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig Liver Dis 33:551–558
Kangro HO, Chong SK, Hardiman A, Heath RB, Walker-Smith JA (1990) A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 98:549–553
Spieker T, Herbst H (2000) Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 157:51–57
Takeda Y, Takada K, Togashi H, Takeda H, Sakano M, Osada Y, Shinzawa H, Takahashi T (2000) Demonstration of Epstein-Barr virus localized in the colonic and ileal mucosa of a patient with ulcerative colitis. Gastrointest Endosc 51:205–209
Van Kruiningen HJ, Poulin M, Garmendia AE, Desreumaux P, Colombel JF, De Hertogh G, Geboes K, Vermeire S, Tsongalis GJ (2007) Search for evidence of recurring or persistent viruses in Crohn’s disease. APMIS 115:962–968
Smith KA, Efstathiou S, Cooke A (2007) Murine gammaherpesvirus-68 infection alters self-antigen presentation and type 1 diabetes onset in NOD mice. J Immunol 179:7325–7333
Pane JA, Coulson BS (2015) Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes. Diabetologia 58:1149–1159
Gale EA (2012) Viruses and type 1 diabetes: ignorance acquires a better vocabulary. Clin Exp Immunol 168:1–4
Coppieters KT, Boettler T, von Herrath M (2012) Virus infections in type 1 diabetes. Cold Spring Harb Perspect Med 2:a007682
Martin AP, Alexander-Brett JM, Canasto-Chibuque C, Garin A, Bromberg JS, Fremont DH, Lira SA (2007) The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. J Immunol 178:4623–4631
Gangadharan B, Dutia BM, Rhind SM, Nash AA (2009) Murid herpesvirus-4 induces chronic inflammation of intrahepatic bile ducts in mice deficient in gamma-interferon signalling. Hepatol Res 39:187–194
Spiekerkoetter E, Alvira CM, Kim YM, Bruneau A, Pricola KL, Wang L, Ambartsumian N, Rabinovitch M (2008) Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am J Physiol Lung Cell Mol Physiol 294:L276–L289
Kim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S, Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M (2011) Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. Am J Pathol 179:1560–1572
Peacock JW, Bost KL (2000) Infection of intestinal epithelial cells and development of systemic disease following gastric instillation of murine gammaherpesvirus-68. J Gen Virol 81:421–429
Olivadoti MD, Weinberg JB, Toth LA, Opp MR (2011) Sleep and fatigue in mice infected with murine gammaherpesvirus 68. Brain Behav Immun 25:696–705
Speck SH, Ganem D (2010) Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 8:100–115
Acknowledgments
This work was supported by the grant (CA167065, J.C.F) from the National Cancer Institute of the National Institutes of Health and the grant (81371825, X.Z.L) from Natural Science Foundation of China.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Dong, S., Forrest, J.C., Liang, X. (2017). Murine Gammaherpesvirus 68: A Small Animal Model for Gammaherpesvirus-Associated Diseases. In: Cai, Q., Yuan, Z., Lan, K. (eds) Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. Advances in Experimental Medicine and Biology, vol 1018. Springer, Singapore. https://doi.org/10.1007/978-981-10-5765-6_14
Download citation
DOI: https://doi.org/10.1007/978-981-10-5765-6_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-5764-9
Online ISBN: 978-981-10-5765-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)